CYP3A5 polymorphisms and individualized tacrolimus therapy after liver transplantation
10.12464/j.issn.1674-7445.2025221
- VernacularTitle:CYP3A5基因多态性与肝移植术后他克莫司个体化用药
- Author:
Xinyu LI
1
;
Xiangyu ZHONG
1
Author Information
1. Department of Biliary-Pancreatic Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
- Publication Type:ReviewArticle
- Keywords:
Liver transplantation;
Tacrolimus;
Rejection;
Cytochrome P450;
Genetic polymorphism;
Individualized therapy;
Pharmacokinetics;
Precision medicine
- From:
Organ Transplantation
2026;17(1):157-163
- CountryChina
- Language:Chinese
-
Abstract:
Tacrolimus is the cornerstone immunosuppressant after liver transplantation, effectively reducing the risk of post-operative rejection. However, optimizing its clinical dosage remains a major challenge. Cytochrome P450 (CYP) 3A5 is the principal enzyme governing tacrolimus metabolism and therefore dominates the metabolic process of the drug. CYP3A5 genetic polymorphisms are a key determinant of inter-patient variability of metabolic capacities and adverse clinical outcomes. In this article the population-specific distribution of CYP3A5 polymorphisms, the principal factors modulating early tacrolimus metabolism after liver transplantation and the clinical implementation of genotype-guided individualized dosing regimens were summarized. The aim is to provide a theoretical foundation for precise tacrolimus dosing strategies in liver transplantation, explore the feasibility of personalized medication approaches, and promote the practice of precision medicine in the field of organ transplantation.
